-
1
-
-
84896335556
-
Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia
-
Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med 2014;6:224ra25.
-
(2014)
Sci Transl Med
, vol.6
-
-
Davila, M.L.1
Riviere, I.2
Wang, X.3
Bartido, S.4
Park, J.5
Curran, K.6
-
2
-
-
84923118622
-
Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor
-
Kochenderfer JN, Dudley ME, Kassim SH, Somerville RP, Carpenter RO, Stetler-Stevenson M, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol 2015;33:540–9.
-
(2015)
J Clin Oncol
, vol.33
, pp. 540-549
-
-
Kochenderfer, J.N.1
Dudley, M.E.2
Kassim, S.H.3
Somerville, R.P.4
Carpenter, R.O.5
Stetler-Stevenson, M.6
-
3
-
-
84908073316
-
Chimeric antigen receptor T cells for sustained remissions in leukemia
-
Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 2014;371:1507–17.
-
(2014)
N Engl J Med
, vol.371
, pp. 1507-1517
-
-
Maude, S.L.1
Frey, N.2
Shaw, P.A.3
Aplenc, R.4
Barrett, D.M.5
Bunin, N.J.6
-
4
-
-
84940881287
-
Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia
-
Porter DL, Hwang WT, Frey NV, Lacey SF, Shaw PA, Loren AW, et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med 2015;7:303ra139.
-
(2015)
Sci Transl Med
, vol.7
-
-
Porter, D.L.1
Hwang, W.T.2
Frey, N.V.3
Lacey, S.F.4
Shaw, P.A.5
Loren, A.W.6
-
5
-
-
84974555520
-
CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
-
Turtle CJ, Hanafi LA, Berger C, Gooley TA, Cherian S, Hudecek M, et al. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J Clin Invest 2016;126:2123–38.
-
(2016)
J Clin Invest
, vol.126
, pp. 2123-2138
-
-
Turtle, C.J.1
Hanafi, L.A.2
Berger, C.3
Gooley, T.A.4
Cherian, S.5
Hudecek, M.6
-
6
-
-
84988805188
-
Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptormodified T cells
-
Turtle CJ, Hanafi LA, Berger C, Hudecek M, Pender B, Robinson E, et al. Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptormodified T cells. Sci Transl Med 2016;8:355ra116.
-
(2016)
Sci Transl Med
, vol.8
-
-
Turtle, C.J.1
Hanafi, L.A.2
Berger, C.3
Hudecek, M.4
Pender, B.5
Robinson, E.6
-
7
-
-
84988984072
-
CD19-targeted chimeric antigen receptor-modified T cell immunotherapy for B cell malignancies
-
Turtle CJ, Riddell SR, Maloney DG. CD19-targeted chimeric antigen receptor-modified T cell immunotherapy for B cell malignancies. Clin Pharmacol Ther 2016;100:252–8.
-
(2016)
Clin Pharmacol Ther
, vol.100
, pp. 252-258
-
-
Turtle, C.J.1
Riddell, S.R.2
Maloney, D.G.3
-
8
-
-
84977477922
-
Toxicities of chimeric antigen receptor T cells: Recognition and management
-
Brudno JN, Kochenderfer JN. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood 2016;127:3321–30.
-
(2016)
Blood
, vol.127
, pp. 3321-3330
-
-
Brudno, J.N.1
Kochenderfer, J.N.2
-
9
-
-
84904097189
-
Current concepts in the diagnosis and management of cytokine release syndrome
-
Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood 2014;124:188–95.
-
(2014)
Blood
, vol.124
, pp. 188-195
-
-
Lee, D.W.1
Gardner, R.2
Porter, D.L.3
Louis, C.U.4
Ahmed, N.5
Jensen, M.6
-
10
-
-
84882637960
-
Biomarkers of endothelial activation/dysfunction in infectious diseases
-
Page AV, Liles WC. Biomarkers of endothelial activation/dysfunction in infectious diseases. Virulence 2013;4:507–16.
-
(2013)
Virulence
, vol.4
, pp. 507-516
-
-
Page, A.V.1
Liles, W.C.2
-
11
-
-
84931291702
-
VWF excess and ADAMTS13 deficiency: A unifying pathomechanism linking inflammation to thrombosis in DIC, malaria, and TTP
-
Schwameis M, Schörgenhofer C, Assinger A, Steiner MM, Jilma B. VWF excess and ADAMTS13 deficiency: a unifying pathomechanism linking inflammation to thrombosis in DIC, malaria, and TTP. Thromb Haemost 2015;113:708–18.
-
(2015)
Thromb Haemost
, vol.113
, pp. 708-718
-
-
Schwameis, M.1
Schörgenhofer, C.2
Assinger, A.3
Steiner, M.M.4
Jilma, B.5
-
12
-
-
0037447930
-
Von Willebrand factor targets IL-8 to Weibel- Palade bodies in an endothelial cell line
-
Romani de Wit T, de Leeuw HP, Rondaij MG, de Laaf RT, Sellink E, Brinkman HJ, et al. Von Willebrand factor targets IL-8 to Weibel- Palade bodies in an endothelial cell line. Exp Cell Res 2003;286:67–74.
-
(2003)
Exp Cell Res
, vol.286
, pp. 67-74
-
-
Romani De Wit, T.1
De Leeuw, H.P.2
Rondaij, M.G.3
De Laaf, R.T.4
Sellink, E.5
Brinkman, H.J.6
-
13
-
-
84958095360
-
Highdensity lipoprotein modulates thrombosis by preventing von Willebrand factor self-association and subsequent platelet adhesion
-
Chung DW, Chen J, Ling M, Fu X, Blevins T, Parsons S, et al. Highdensity lipoprotein modulates thrombosis by preventing von Willebrand factor self-association and subsequent platelet adhesion. Blood 2016;127:637–45.
-
(2016)
Blood
, vol.127
, pp. 637-645
-
-
Chung, D.W.1
Chen, J.2
Ling, M.3
Fu, X.4
Blevins, T.5
Parsons, S.6
-
14
-
-
0026638736
-
Plasma cytokine levels in thrombotic thrombocytopenic purpura
-
Wada H, Kaneko T, Ohiwa M, Tanigawa M, Tamaki S, Minami N, et al. Plasma cytokine levels in thrombotic thrombocytopenic purpura. Am J Hematol 1992;40:167–70.
-
(1992)
Am J Hematol
, vol.40
, pp. 167-170
-
-
Wada, H.1
Kaneko, T.2
Ohiwa, M.3
Tanigawa, M.4
Tamaki, S.5
Minami, N.6
-
15
-
-
77649225653
-
The blood brain barrier and the role of cytokines in neuropsychiatry
-
Yarlagadda A, Alfson E, Clayton AH. The blood brain barrier and the role of cytokines in neuropsychiatry. Psychiatry (Edgmont) 2009;6:18–22.
-
(2009)
Psychiatry (Edgmont)
, vol.6
, pp. 18-22
-
-
Yarlagadda, A.1
Alfson, E.2
Clayton, A.H.3
-
16
-
-
78649467527
-
Pericytes regulate the blood-brain barrier
-
Armulik A, Genové G, Mäe M, Nisancioglu MH, Wallgard E, Niaudet C, et al. Pericytes regulate the blood-brain barrier. Nature 2010; 468:557–61.
-
(2010)
Nature
, vol.468
, pp. 557-561
-
-
Armulik, A.1
Genové, G.2
Mäe, M.3
Nisancioglu, M.H.4
Wallgard, E.5
Niaudet, C.6
-
18
-
-
84926099033
-
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: A multicentre, single-arm, phase 2 study
-
Topp MS, Gökbuget N, Stein AS, Zugmaier G, O’Brien S, Bargou RC, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol 2015;16:57–66.
-
(2015)
Lancet Oncol
, vol.16
, pp. 57-66
-
-
Topp, M.S.1
Gökbuget, N.2
Stein, A.S.3
Zugmaier, G.4
O’Brien, S.5
Bargou, R.C.6
-
19
-
-
85018417861
-
Tumour ischaemia by interferon-γ resembles physiological blood vessel regression
-
Kammertoens T, Friese C, Arina A, Idel C, Briesemeister D, Rothe M, et al. Tumour ischaemia by interferon-γ resembles physiological blood vessel regression. Nature 2017;545:98–102.
-
(2017)
Nature
, vol.545
, pp. 98-102
-
-
Kammertoens, T.1
Friese, C.2
Arina, A.3
Idel, C.4
Briesemeister, D.5
Rothe, M.6
-
20
-
-
80055079785
-
Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: Long-term results of the HLH-94 treatment protocol
-
Trottestam H, Horne A, Aricò M, Egeler RM, Filipovich AH, Gadner H, et al. Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: long-term results of the HLH-94 treatment protocol. Blood 2011;118:4577–84.
-
(2011)
Blood
, vol.118
, pp. 4577-4584
-
-
Trottestam, H.1
Horne, A.2
Aricò, M.3
Egeler, R.M.4
Filipovich, A.H.5
Gadner, H.6
-
21
-
-
84963704157
-
Measuring IL-6 and sIL-6R in serum from patients treated with tocilizumab and/or siltuximab following CAR T cell therapy
-
Chen F, Teachey DT, Pequignot E, Frey N, Porter D, Maude SL, et al. Measuring IL-6 and sIL-6R in serum from patients treated with tocilizumab and/or siltuximab following CAR T cell therapy. J Immunol Methods 2016;434:1–8.
-
(2016)
J Immunol Methods
, vol.434
, pp. 1-8
-
-
Chen, F.1
Teachey, D.T.2
Pequignot, E.3
Frey, N.4
Porter, D.5
Maude, S.L.6
-
22
-
-
58149154996
-
Mechanisms and pathologic significances in increase in serum interleukin- 6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease
-
Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T. Mechanisms and pathologic significances in increase in serum interleukin- 6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood 2008;112:3959–64.
-
(2008)
Blood
, vol.112
, pp. 3959-3964
-
-
Nishimoto, N.1
Terao, K.2
Mima, T.3
Nakahara, H.4
Takagi, N.5
Kakehi, T.6
-
23
-
-
84989908039
-
Dysregulation of angiopoietin-1 plays a mechanistic role in the pathogenesis of cerebral malaria
-
Higgins SJ, Purcell LA, Silver KL, Tran V, Crowley V, Hawkes M, et al. Dysregulation of angiopoietin-1 plays a mechanistic role in the pathogenesis of cerebral malaria. Sci Transl Med 2016;8:358ra128.
-
(2016)
Sci Transl Med
, vol.8
-
-
Higgins, S.J.1
Purcell, L.A.2
Silver, K.L.3
Tran, V.4
Crowley, V.5
Hawkes, M.6
-
24
-
-
84959349563
-
Angiopoietin- 2-induced blood-brain barrier compromise and increased stroke size are rescued by VE-PTP-dependent restoration of Tie2 signaling
-
Gurnik S, Devraj K, Macas J, Yamaji M, Starke J, Scholz A, et al. Angiopoietin- 2-induced blood-brain barrier compromise and increased stroke size are rescued by VE-PTP-dependent restoration of Tie2 signaling. Acta Neuropathol 2016;131:753–73.
-
(2016)
Acta Neuropathol
, vol.131
, pp. 753-773
-
-
Gurnik, S.1
Devraj, K.2
Macas, J.3
Yamaji, M.4
Starke, J.5
Scholz, A.6
-
25
-
-
33644862000
-
A rapid enzyme-linked assay for ADAMTS-13
-
Wu JJ, Fujikawa K, Lian EC, McMullen BA, Kulman JD, Chung DW. A rapid enzyme-linked assay for ADAMTS-13. J Thromb Haemost 2006;4:129–36.
-
(2006)
J Thromb Haemost
, vol.4
, pp. 129-136
-
-
Wu, J.J.1
Fujikawa, K.2
Lian, E.C.3
McMullen, B.A.4
Kulman, J.D.5
Chung, D.W.6
|